Celldex Therapeutics, based in Hampton, New Jersey, develops novel therapeutics targeting mast cell-mediated diseases and employs 160 staff. Their pipeline includes Barzolvolimab and the bispecific antibody CDX-585 for inflammatory diseases and oncology.
CLDX filed a patent for "cd27 agonists" on Fri, May 17, 2024. The patent was officially published on Thu, February 20, 2025.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.